HemOnc Today


Postsurgical surveillance sufficient for men with stage I seminoma

Most men with stage I seminoma who undergo successful surgery for their cancer can be followed with surveillance, according to results of a long-term study in Denmark.

Posted May 16, 2013

SEER database accurately classified nearly all renal cell carcinoma cases

Nearly all renal cell carcinoma cases were correctly classified in the SEER database, with a higher positive predictive value for clear cell renal cell carcinoma than for papillary or chromophobe renal cell carcinoma, according to study results.

Posted May 2, 2013

Advisory committee votes against tivozanib for RCC

An FDA advisory panel today rejected tivozanib as a treatment for advanced renal cell carcinoma.

Posted May 2, 2013

Nanoparticles offer ‘infinite’ possibilities for cancer treatment

After more than 3 decades of intense research, nanotechnology has moved out of the fiction realm and into the scientific.

Posted May 1, 2013

Intermittent ADT failed to improve survival in metastatic prostate cancer

Intermittent androgen deprivation therapy failed to improve survival rates or quality of life compared with continuous therapy in patients with metastatic hormone-sensitive prostate cancer, according to study results.

Posted April 30, 2013

Prostate cancer risk doubles in patients with Lynch syndrome

The cumulative lifetime risk for prostate cancer was twice as high in patients with Lynch syndrome compared with the general population, according to study results.

Posted April 24, 2013

Pirarubicin instilled intravesically reduced bladder recurrence after nephroureterectomy

A single early intravesical instillation of pirarubicin yielded significant reductions in bladder recurrence rates in a cohort of patients with urothelial carcinoma, study results showed.

Posted April 19, 2013

Zibotentan/docetaxel failed to improve OS in metastatic castration-resistant prostate cancer

Docetaxel plus zibotentan failed to significantly improve OS in men with metastatic castration-resistant prostate cancer, according to final phase 3 data from the ENTHUSE clinical trial program.

Posted April 17, 2013

Genetic link to bladder cancer risk, mortality observed

Variations in the regulator of G-protein signaling pathway were associated with increases in disease progression and death among certain populations of patients with bladder cancer, study results showed.

Posted April 12, 2013

ACP: Shared decision-making approach urged before PSA testing

Clinicians should inform men aged 50 to 69 years of the limited benefits and significant harms of the prostate-specific antigen test before undergoing screening for prostate cancer, according to new recommendations issued recently by the American College of Physicians.

Posted April 9, 2013


© 2014 SLACK, Inc.